Alaunos Therapeutics (NASDAQ:TCRT) Issues Earnings Results

Alaunos Therapeutics (NASDAQ:TCRT) announced its quarterly earnings data on Friday. The company reported ($0.55) earnings per share for the quarter, Zacks reports.

Alaunos Therapeutics Trading Up 4.2%

NASDAQ TCRT traded up $0.12 on Friday, reaching $2.97. 34,528 shares of the company were exchanged, compared to its average volume of 305,418. The business’s fifty day moving average price is $2.72 and its 200 day moving average price is $2.96. The stock has a market capitalization of $6.90 million, a P/E ratio of -1.21 and a beta of -0.90. Alaunos Therapeutics has a fifty-two week low of $1.31 and a fifty-two week high of $6.20.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Alaunos Therapeutics in a research note on Tuesday. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.